8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 5, 2026·SEC
Material company update
Jan 12, 2026·SEC
Adaptive Biotechnologies Corporation(ADPT)Earnings, Financials & Key Ratios
ADPT•NASDAQ
$14.43
$2.22B mkt cap·Price updated May 6, 2026
AboutAdaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Show more
- Revenue$277M+54.8%
- EBITDA-$39M+72.6%
- Net Income-$59M+62.7%
- EPS (Diluted)-0.39+63.9%
- Gross Margin74.24%+24.3%
- EBITDA Margin-14.19%+82.3%
- Operating Margin-20.62%+77.3%
- Net Margin-21.48%+75.9%
- ROE-27.84%+55.4%
- ROIC-12.62%+69.7%
- Debt/Equity1.25+182.5%
- Interest Coverage-4.05+68.3%
ADPT Key Insights
Adaptive Biotechnologies Corporation (ADPT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 16.5%
- ✓Strong 5Y sales CAGR of 23.0%
✗Weaknesses
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ADPT Price & Volume
Adaptive Biotechnologies Corporation (ADPT) stock price & volume — 10-year historical chart
Loading chart...
ADPT Growth Metrics
Adaptive Biotechnologies Corporation (ADPT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years23%
3 Years14.34%
TTM55.87%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM64.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM65.47%
Return on Capital
10 Years-20.77%
5 Years-25.67%
3 Years-26.56%
Last Year-13.22%
ADPT Recent Earnings
Adaptive Biotechnologies Corporation (ADPT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 5, 2026EPS
$0.13
Est $0.16
+18.8%
Revenue
$71M
Est $61M
+16.2%
Q1 2026
Feb 5, 2026EPS
$0.09
Est $0.19
+52.6%
Revenue
$72M
Est $61M
+17.7%
Q4 2025
Nov 5, 2025EPS
$0.15
Est $0.16
+6.3%
Revenue
$94M
Est $59M
+58.2%
Q3 2025
Aug 5, 2025EPS
$0.17
Est $0.24
+29.2%
Revenue
$59M
Est $55M
+6.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.13vs $0.16+18.8% | $71Mvs $61M+16.2% |
| Q1 2026 | Feb 5, 2026 | $0.09vs $0.19+52.6% | $72Mvs $61M+17.7% |
| Q4 2025 | Nov 5, 2025 | $0.15vs $0.16+6.3% | $94Mvs $59M+58.2% |
| Q3 2025 | Aug 5, 2025 | $0.17vs $0.24+29.2% | $59Mvs $55M+6.3% |
Based on last 12 quarters of dataView full earnings history →
ADPT Peer Comparison
Adaptive Biotechnologies Corporation (ADPT) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 PACB | 516.17M | 1.71 | -1.60 | -23.19% | -325.8% | -13.95% | 1.33 | |
 TWST | 3.71B | 59.53 | -45.79 | 20.32% | -19.85% | -17.46% | 0.29 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 | |
 FLGT | 443.83M | 14.92 | -7.57 | 13.83% | -18.75% | -5.42% | 0.00 | |
 CDNA | 1.08B | 20.94 | -52.35 | 13.79% | -1.98% | -2.61% | 0.06 | |
 VCYT | 3.29B | 41.19 | 50.23 | 16.01% | 16.25% | 6.86% | 0.03 |
Compare ADPT vs Peers
Adaptive Biotechnologies Corporation (ADPT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADPT Income Statement
Adaptive Biotechnologies Corporation (ADPT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 38.45M | 55.66M | 85.07M | 98.38M | 154.34M | 185.31M | 170.28M | 178.96M | 276.98M | 295.41M |
| Revenue Growth % | - | 44.77% | 52.83% | 15.65% | 56.88% | 20.06% | -8.11% | 5.1% | 54.77% | 55.87% |
| Cost of Goods Sold | 15.68M | 19.67M | 22.27M | 22.53M | 49.3M | 57.91M | 75.55M | 72.08M | 71.36M | 73.09M |
| COGS % of Revenue | 40.78% | 35.33% | 26.18% | 22.9% | 31.94% | 31.25% | 44.37% | 40.28% | 25.76% | - |
| Gross Profit | 22.77M▲ 0% | 35.99M▲ 58.1% | 62.8M▲ 74.5% | 75.85M▲ 20.8% | 105.04M▲ 38.5% | 127.4M▲ 21.3% | 94.72M▼ 25.6% | 106.88M▲ 12.8% | 205.62M▲ 92.4% | 222.32M▲ 0% |
| Gross Margin % | 59.22% | 64.67% | 73.82% | 77.1% | 68.06% | 68.75% | 55.63% | 59.72% | 74.24% | 75.26% |
| Gross Profit Growth % | - | 58.09% | 74.46% | 20.79% | 38.48% | 21.28% | -25.65% | 12.83% | 92.39% | - |
| Operating Expenses | 66.4M | 85.75M | 141.19M | 228.67M | 314.01M | 327.58M | 321.76M | 269.43M | 262.74M | 269.04M |
| OpEx % of Revenue | 172.71% | 154.05% | 165.96% | 232.43% | 203.45% | 176.78% | 188.96% | 150.55% | 94.86% | - |
| Selling, General & Admin | 32.71M | 44.9M | 68.78M | 110.89M | 169.97M | 184.13M | 172.51M | 157.56M | 167.27M | 174.16M |
| SG&A % of Revenue | 85.09% | 80.66% | 80.86% | 112.72% | 110.12% | 99.36% | 101.31% | 88.05% | 60.39% | - |
| Research & Development | 32M | 39.16M | 70.7M | 116.07M | 142.34M | 141.76M | 122.12M | 102.95M | 93.77M | 93.19M |
| R&D % of Revenue | 83.22% | 70.35% | 83.11% | 117.98% | 92.22% | 76.5% | 71.72% | 57.53% | 33.85% | - |
| Other Operating Expenses | 1.69M | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 27.13M | 8.91M | 1.7M | 1.7M |
| Operating Income | -44.48M▲ 0% | -49.76M▼ 11.9% | -78.39M▼ 57.6% | -152.82M▼ 94.9% | -208.97M▼ 36.7% | -200.19M▲ 4.2% | -227.03M▼ 13.4% | -162.55M▲ 28.4% | -57.12M▲ 64.9% | -46.73M▲ 0% |
| Operating Margin % | -115.68% | -89.39% | -92.15% | -155.33% | -135.39% | -108.03% | -133.33% | -90.83% | -20.62% | -15.82% |
| Operating Income Growth % | - | -11.87% | -57.55% | -94.94% | -36.74% | 4.2% | -13.41% | 28.4% | 64.86% | - |
| EBITDA | -38.68M | -43.76M | -70.6M | -144.34M | -195.01M | -179.27M | -204.8M | -143.29M | -39.29M | -33.62M |
| EBITDA Margin % | -100.6% | -78.61% | -82.99% | -146.72% | -126.35% | -96.74% | -120.28% | -80.07% | -14.19% | -11.38% |
| EBITDA Growth % | - | -13.13% | -61.35% | -104.45% | -35.1% | 8.07% | -14.25% | 30.03% | 72.58% | 73.36% |
| D&A (Non-Cash Add-back) | 5.8M | 6M | 7.79M | 8.47M | 13.95M | 20.92M | 22.23M | 19.26M | 17.83M | 13.1M |
| EBIT | -43.63M | -49.76M | -78.39M | -152.82M | -207.3M | -196.13M | -211.5M | -148.01M | -47.68M | -20.75M |
| Net Interest Income | 1.64M | 3.31M | 9.79M | 6.59M | 1.67M | -182K | 1.73M | 2.95M | -2.33M | -2.11M |
| Interest Income | 1.64M | 3.31M | 9.79M | 6.59M | 1.67M | 4.06M | 15.53M | 14.53M | 9.44M | 6.76M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 4.24M | 13.8M | 11.58M | 11.78M | 5.98M |
| Other Income/Expense | 1.64M | 3.31M | 9.79M | 6.59M | 1.67M | -182K | 1.73M | 2.95M | -2.33M | -2.93M |
| Pretax Income | -42.83M▲ 0% | -46.45M▼ 8.4% | -68.61M▼ 47.7% | -146.23M▼ 113.1% | -207.3M▼ 41.8% | -200.37M▲ 3.3% | -225.3M▼ 12.4% | -159.59M▲ 29.2% | -59.46M▲ 62.7% | -49.66M▲ 0% |
| Pretax Margin % | -111.4% | -83.44% | -80.65% | -148.63% | -134.31% | -108.13% | -132.32% | -89.18% | -21.47% | -16.81% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -42.83M▲ 0% | -46.45M▼ 8.4% | -68.61M▼ 47.7% | -146.23M▼ 113.1% | -207.28M▼ 41.8% | -200.19M▲ 3.4% | -225.25M▼ 12.5% | -159.49M▲ 29.2% | -59.5M▲ 62.7% | -49.68M▲ 0% |
| Net Margin % | -111.4% | -83.44% | -80.65% | -148.63% | -134.3% | -108.03% | -132.29% | -89.12% | -21.48% | -16.82% |
| Net Income Growth % | - | -8.44% | -47.71% | -113.14% | -41.75% | 3.42% | -12.52% | 29.19% | 62.69% | 64.97% |
| Net Income (Continuing) | -42.83M | -46.45M | -68.61M | -146.23M | -207.3M | -200.37M | -225.3M | -159.59M | -59.46M | -49.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 110K | -67K | -121K | -224K | 6.21M | 7.9M |
| EPS (Diluted) | -0.41▲ 0% | -0.44▼ 7.3% | -0.47▼ 6.8% | -1.06▼ 125.5% | -1.46▼ 37.7% | -1.00▲ 31.5% | -1.56▼ 56.0% | -1.08▲ 30.8% | -0.39▲ 63.9% | -0.32▲ 0% |
| EPS Growth % | - | -7.32% | -6.82% | -125.53% | -37.74% | 31.51% | -56% | 30.77% | 63.89% | 65.47% |
| EPS (Basic) | -0.41 | -0.44 | -0.47 | -1.06 | -1.46 | -1.00 | -1.56 | -1.08 | -0.39 | - |
| Diluted Shares Outstanding | 105.43M | 105.43M | 124.34M | 131.22M | 140.35M | 142.52M | 144.38M | 147.1M | 151.72M | 155.52M |
| Basic Shares Outstanding | 105.43M | 105.43M | 124.34M | 131.22M | 140.35M | 142.52M | 144.38M | 147.1M | 151.72M | 155.52M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ADPT Balance Sheet
Adaptive Biotechnologies Corporation (ADPT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 205.25M | 180.72M | 612.69M | 726.91M | 402.75M | 562.15M | 410.19M | 283.75M | 300.19M | 291.81M |
| Cash & Short-Term Investments | 192.15M | 165.02M | 576.87M | 688.27M | 353.06M | 498.2M | 346.4M | 222.29M | 226.98M | 218.33M |
| Cash Only | 85.31M | 55.03M | 96.58M | 123.44M | 139.06M | 90.03M | 65.06M | 47.92M | 70.5M | 77.58M |
| Short-Term Investments | 106.84M | 109.99M | 480.29M | 564.83M | 214M | 408.17M | 281.34M | 174.37M | 156.49M | 140.75M |
| Accounts Receivable | 5.58M | 4.81M | 12.68M | 10.05M | 17.41M | 40.06M | 37.97M | 41.73M | 50.37M | 48.31M |
| Days Sales Outstanding | 52.99 | 31.52 | 54.39 | 37.27 | 41.17 | 78.9 | 81.39 | 85.11 | 66.37 | 58.47 |
| Inventory | 4.79M | 7.84M | 9.07M | 14.06M | 19.26M | 14.45M | 14.45M | 8.44M | 9.82M | 11.21M |
| Days Inventory Outstanding | 111.55 | 145.46 | 148.61 | 227.83 | 142.61 | 91.1 | 69.8 | 42.74 | 50.23 | 49.14 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 9.44M | 11.37M | 11.29M | 13.02M | 13.95M |
| Total Non-Current Assets | 157.24M | 151.97M | 299.61M | 389.5M | 520.6M | 294.47M | 250.95M | 255.62M | 212.55M | 214.14M |
| Property, Plant & Equipment | 13.95M | 19.13M | 60.35M | 139.04M | 172.94M | 164.21M | 120.32M | 94.38M | 74.72M | 71.02M |
| Fixed Asset Turnover | 2.76x | 2.91x | 1.41x | 0.71x | 0.89x | 1.13x | 1.42x | 1.90x | 3.71x | 3.82x |
| Goodwill | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M |
| Intangible Assets | 15.32M | 13.63M | 11.93M | 10.22M | 8.53M | 6.83M | 5.13M | 3.42M | 1.73M | 1.31M |
| Long-Term Investments | 8.9M | 247K | 105.44M | 118.53M | 217.15M | 0 | 0 | 33.66M | 15.92M | 46.75M |
| Other Non-Current Assets | 86K | 247K | 2.92M | 2.74M | 3.01M | 4.46M | 6.52M | 5.18M | 1.21M | 30.61M |
| Total Assets | 362.49M▲ 0% | 332.69M▼ 8.2% | 912.3M▲ 174.2% | 1.12B▲ 22.4% | 923.34M▼ 17.3% | 856.62M▼ 7.2% | 661.13M▼ 22.8% | 539.38M▼ 18.4% | 512.74M▼ 4.9% | 505.94M▲ 0% |
| Asset Turnover | 0.11x | 0.17x | 0.09x | 0.09x | 0.17x | 0.22x | 0.26x | 0.33x | 0.54x | 0.59x |
| Asset Growth % | - | -8.22% | 174.22% | 22.37% | -17.29% | -7.23% | -22.82% | -18.42% | -4.94% | -33.14% |
| Total Current Liabilities | 21M | 22.8M | 78.31M | 105.2M | 113.81M | 109.79M | 88.02M | 98.05M | 89.92M | 87.01M |
| Accounts Payable | 1.96M | 1.79M | 4.45M | 3.24M | 3.31M | 8.08M | 7.72M | 7.26M | 6.47M | 9.62M |
| Days Payables Outstanding | 45.72 | 33.27 | 72.97 | 52.44 | 24.48 | 50.95 | 37.29 | 36.79 | 33.08 | 41.52 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.56M | 8.51M |
| Deferred Revenue (Current) | 14.05M | 12.7M | 60.99M | 73.32M | 80.46M | 64.11M | 48.63M | 55.69M | 45.19M | 191.23M |
| Other Current Liabilities | 1.93M | 3.67M | 8.49M | 11.95M | 15.64M | 15.94M | 13.69M | 16.7M | 7.7M | 19.49M |
| Current Ratio | 9.77x | 7.93x | 7.82x | 6.91x | 3.54x | 5.12x | 4.66x | 2.89x | 3.34x | 3.34x |
| Quick Ratio | 9.54x | 7.58x | 7.71x | 6.78x | 3.37x | 4.99x | 4.50x | 2.81x | 3.23x | 3.23x |
| Cash Conversion Cycle | 118.82 | 143.7 | 130.03 | 212.66 | 159.3 | 119.04 | 113.9 | 91.06 | 83.52 | 66.09 |
| Total Non-Current Liabilities | 566.1M | 568M | 262.95M | 267.95M | 205.44M | 282.73M | 264.84M | 238.84M | 197.82M | 194.69M |
| Long-Term Debt | 0 | 561.19M | 0 | 0 | 0 | 0 | 0 | 0 | 196.79M | 69.11M |
| Capital Lease Obligations | 0 | 0 | 36.61M | 104.33M | 106.69M | 98.77M | 89.39M | 79.15M | 70.23M | 217M |
| Deferred Tax Liabilities | 0 | -561.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 566.1M | 6.1M | 7.01M | 0 | 0 | 125.36M | 130.66M | 132.43M | -70.21M | 315.31M |
| Total Liabilities | 587.11M | 590.8M | 341.26M | 373.15M | 319.24M | 392.52M | 352.86M | 336.89M | 287.74M | 281.7M |
| Total Debt | 561.67M | 561.19M | 36.61M | 107.86M | 111.74M | 108M | 98.77M | 89.39M | 280.58M | 77.63M |
| Net Debt | 476.37M | 506.16M | -59.97M | -15.57M | -27.32M | 17.97M | 33.71M | 41.47M | 210.09M | 47K |
| Debt / Equity | - | - | 0.06x | 0.15x | 0.18x | 0.23x | 0.32x | 0.44x | 1.25x | 1.25x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -2.31x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Interest Coverage | - | - | - | - | - | -46.28x | -15.33x | -12.78x | -4.05x | -3.47x |
| Total Equity | -224.62M▲ 0% | -258.11M▼ 14.9% | 571.04M▲ 321.2% | 743.27M▲ 30.2% | 604.1M▼ 18.7% | 464.1M▼ 23.2% | 308.28M▼ 33.6% | 202.49M▼ 34.3% | 225M▲ 11.1% | 224.24M▲ 0% |
| Equity Growth % | - | -14.91% | 321.24% | 30.16% | -18.72% | -23.18% | -33.57% | -34.32% | 11.12% | -5.27% |
| Book Value per Share | -2.13 | -2.45 | 4.59 | 5.66 | 4.30 | 3.26 | 2.14 | 1.38 | 1.48 | 1.44 |
| Total Shareholders' Equity | -224.62M | -258.11M | 571.04M | 743.27M | 603.99M | 464.17M | 308.4M | 202.71M | 218.79M | 216.34M |
| Common Stock | 1K | 1K | 12K | 14K | 14K | 14K | 14K | 14K | 15K | 16K |
| Retained Earnings | -249.42M | -295.91M | -365.48M | -511.61M | -718.89M | -919.08M | -1.14B | -1.3B | -1.36B | -1.38B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -166K | -107K | 671K | 893K | -1.14M | -4.12M | 215K | 166K | 253K | -28K |
| Minority Interest | 0 | 0 | 0 | 0 | 110K | -67K | -121K | -224K | 6.21M | 7.9M |
ADPT Cash Flow Statement
Adaptive Biotechnologies Corporation (ADPT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -34.86M | -32.26M | 205.4M | -149.68M | -192.73M | -183.94M | -156.32M | -95.21M | -45.99M | -45.99M |
| Operating CF Margin % | -90.66% | -57.95% | 241.45% | -152.14% | -124.87% | -99.26% | -91.81% | -53.2% | -16.6% | - |
| Operating CF Growth % | - | 7.46% | 736.73% | -172.87% | -28.76% | 4.56% | 15.02% | 39.09% | 51.7% | 284.8% |
| Net Income | -42.83M | -46.45M | -68.61M | -146.23M | -207.28M | -200.19M | -225.25M | -159.59M | -59.5M | -49.68M |
| Depreciation & Amortization | 5.8M | 6M | 7.79M | 8.47M | 20.98M | 28.15M | 22.23M | 19.26M | 0 | 12.74M |
| Stock-Based Compensation | 7.01M | 11.15M | 13.12M | 24.76M | 0 | 0 | 0 | 53.61M | 51.48M | 38.01M |
| Deferred Taxes | 637K | -1.24M | -1.88M | 773K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 6K | 5K | 43K | 3.34M | 50.39M | 59.65M | 92.88M | 8.97M | 19.8M | 13.47M |
| Working Capital Changes | -5.47M | -1.72M | 254.93M | -40.8M | -56.82M | -71.55M | -46.18M | -17.45M | -57.77M | -41.62M |
| Change in Receivables | -2.43M | 775K | -7.82M | 2.61M | -7.36M | -22.65M | 2.03M | -3.74M | -8.65M | -4.73M |
| Change in Inventory | -2.7M | -3.05M | -1.23M | -4.99M | -5.2M | 817K | -2.84M | 1.94M | -998K | -1.27M |
| Change in Payables | -1.84M | 1.87M | -2.43M | 5.25M | 3.94M | 7.11M | -5.41M | 671K | 665K | 2.82M |
| Cash from Investing | 36.43M | 736K | -481.7M | -117.04M | 181.21M | 2.9M | 129.65M | 77.79M | 37.95M | 21.52M |
| Capital Expenditures | -2.51M | -6.32M | -11.2M | -18.8M | -61.75M | -16.35M | -10.7M | -3.66M | -2.96M | -2.5M |
| CapEx % of Revenue | 6.52% | 11.35% | 13.17% | 19.11% | 40.01% | 8.82% | 6.28% | 2.05% | 1.07% | - |
| Acquisitions | 85K | 19K | 470.5M | 98.24M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 122K | 19K | -470.5M | -98.24M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 50.03M | 1.25M | 319.92M | 293.59M | 27.15M | 132.26M | 2.25M | 241K | 30.4M | 32.45M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 124.38M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 49.83M | 0 | 320.85M | 272.16M | 26.72M | 7.89M | 2.25M | 241K | 30.4M | 24.95M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 207K | 1.25M | -934K | 21.43M | 429K | 0 | 0 | 0 | 0 | 7.5M |
| Net Change in Cash | 51.61M▲ 0% | -30.27M▼ 158.7% | 43.62M▲ 244.1% | 26.86M▼ 38.4% | 15.63M▼ 41.8% | -49.03M▼ 413.7% | -24.97M▲ 49.1% | -17.18M▲ 31.2% | 22.37M▲ 230.2% | 26.96M▲ 0% |
| Free Cash Flow | -37.36M▲ 0% | -38.58M▼ 3.2% | 194.2M▲ 603.4% | -168.49M▼ 186.8% | -254.47M▼ 51.0% | -200.29M▲ 21.3% | -167.02M▲ 16.6% | -98.88M▲ 40.8% | -48.95M▲ 50.5% | -29.54M▲ 0% |
| FCF Margin % | -97.18% | -69.3% | 228.28% | -171.26% | -164.87% | -108.09% | -98.09% | -55.25% | -17.67% | -10% |
| FCF Growth % | - | -3.25% | 603.42% | -186.76% | -51.04% | 21.29% | 16.61% | 40.8% | 50.5% | 66.72% |
| FCF per Share | -0.35 | -0.37 | 1.56 | -1.28 | -1.81 | -1.41 | -1.16 | -0.67 | -0.32 | -0.32 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.69x | -2.99x | 1.02x | 0.93x | 0.92x | 0.69x | 0.60x | 0.77x | 0.59x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ADPT Key Ratios
Adaptive Biotechnologies Corporation (ADPT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -43.85% | -22.25% | -30.77% | -37.48% | -58.33% | -62.45% | -27.84% | -23.86% |
| Return on Invested Capital (ROIC) | -14.93% | -15.49% | -18.5% | -24.03% | -28.36% | -41.33% | -41.61% | -12.62% | -12.62% |
| Gross Margin | 64.67% | 73.82% | 77.1% | 68.06% | 68.75% | 55.63% | 59.72% | 74.24% | 75.26% |
| Net Margin | -83.44% | -80.65% | -148.63% | -134.3% | -108.03% | -132.29% | -89.12% | -21.48% | -16.82% |
| Debt / Equity | - | 0.06x | 0.15x | 0.18x | 0.23x | 0.32x | 0.44x | 1.25x | 1.25x |
| Interest Coverage | - | - | - | - | -46.28x | -15.33x | -12.78x | -4.05x | -3.47x |
| FCF Conversion | 0.69x | -2.99x | 1.02x | 0.93x | 0.92x | 0.69x | 0.60x | 0.77x | 0.59x |
| Revenue Growth | 44.77% | 52.83% | 15.65% | 56.88% | 20.06% | -8.11% | 5.1% | 54.77% | 55.87% |
ADPT SEC Filings & Documents
Adaptive Biotechnologies Corporation (ADPT) SEC filings — annual & quarterly reports (10-K, 10-Q)
ADPT Frequently Asked Questions
Adaptive Biotechnologies Corporation (ADPT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Adaptive Biotechnologies Corporation (ADPT) reported $295.4M in revenue for fiscal year 2025. This represents a 668% increase from $38.4M in 2017.
Adaptive Biotechnologies Corporation (ADPT) grew revenue by 54.8% over the past year. This is strong growth.
Adaptive Biotechnologies Corporation (ADPT) reported a net loss of $49.7M for fiscal year 2025.
Dividend & Returns
Adaptive Biotechnologies Corporation (ADPT) has a return on equity (ROE) of -27.8%. Negative ROE indicates the company is unprofitable.
Adaptive Biotechnologies Corporation (ADPT) had negative free cash flow of $29.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More ADPT
Adaptive Biotechnologies Corporation (ADPT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates